UPCOMING SESSIONS in ET
Wed, Apr 8, 2026
10:00 – 11:00 PM UTC
CAR-T Therapy for AL Amyloidosis: What’s New, What’s Real, and What’s Next Heather Landau Click To Register
UPCOMING SESSIONS in ET
Wed, Apr 8, 2026 · 10:00 – 11:00 PM UTC
CAR-T Therapy for AL Amyloidosis: What’s New, What’s Real, and What’s Next
Heather Landau
Click To Register
View all sessions

Dr Gertz on the Investigation of Birtamimab in Mayo Stage IV AL Amyloidosis

Published: May 19, 2023
Category
Community Interviews
Source
https://www.onclive.com/view/dr-gertz-on-the-investigation-of-birtamimab-in-mayo-stage-iv-al-amyloidosis
Details

Morie A. Gertz, MD, chair, General Internal Medicine, Mayo Clinic Comprehensive Cancer Center, discusses the rationale for the phase 3 AFFIRM-AL trial (NCT04973137) in patients with amyloid light chain (AL) amyloidosis and elaborates on the challenges that may arise when enrolling patients to this trial.

Tags